NEW YORK (GenomeWeb) — BGI Europe has inked an exclusive technology transfer deal with Spain's NIM Genetics for BGI Europe's non-invasive prenatal testing technology.
The deal allows NIM to begin offering BGI Europe's NIPT in Spain. The test, called TrisoNIM Advance and marketed as Nifty in other parts of Europe, detects the risk of genetic conditions such as Down syndrome from as early as 10 weeks into the pregnancy.
The deal follows other deals forged by BGI Europe, the European branch of BGI, to make Nifty available in Italy and Poland.